Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05638932 · ClinicalTrials.gov registry record

Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments

A clinical trial of COVID-19, sponsored by Aetion.

Completed
Registry status
1,442
Enrollment target
1
Study location

NCT05638932: Completed study of COVID-19, sponsored by Aetion.

NCT05638932 is a study of COVID-19 that has completed, run by Aetion. The registered enrollment target is 1,442 participants, below the 38,460-participant average among 298 other COVID-19 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05638932, a study of COVID-19, has completed, sponsored by Aetion.

COMPLETED
Registry status
1,442 participants
Enrollment target
1
Study location

Study Summary

To apply and compare two different methodological approaches (one applying diagnostics steps and contingencies and the other not) to the illustrative example described below: Illustrative Example - Objective I aims to characterize the risk of inpatient mortality \[Primary Outcome\] and progression to invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) \[Secondary Outcome\] up to 28 days after interleukin-6 receptor inhibitors (IL6Ri) or janus kinase inhibitor (JAKi) initiation among patients hospitalized with Coronavirus Disease 2019 (COVID-19) who initiate a corticosteroid of interest and require supplemental oxygen / non-invasive ventilation / high flow oxygen (O2/NIV/HFO) (but not IMV/ECMO). Illustrative Example - Objective II aims to characterize the risk of inpatient mortality \[Primary Outcome\] up to 28 days after IL6Ri or JAKi initiation among patients admitted to the ICU at hospital admission with COVID-19 who initiate a CSI and require IMV/ECMO. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) will be estimated and reported for all outcome risks in Illustrative Example objectives.

Primary Outcome

Inpatient mortality up to 28 days after IL6Ri or JAKi initiation

Conditions Studied

Interventions

  • DRUG Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)

Study Locations (1)

New York

  • Aetion, Inc. - New York

Trial Details

FieldValue
Enrollment Target 1,442 participants
Start Date 2020-06-16
Est. Completion 2023-09-25
Aetion

3 total trials

What the finished NCT05638932 record still lists

NCT05638932 is an observational study that tracks outcomes without assigning an intervention. Its 1,442 participants enrollment target places it among the larger protocols in the corpus, below the 38,460-participant average among 298 other COVID-19 trials with a reported enrollment target (96% lower).

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI) is the first listed.

NCT05638932 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05638932 about?

NCT05638932 is a clinical study titled "Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments". To apply and compare two different methodological approaches (one applying diagnostics steps and contingencies and the other not) to the illustrative example described below: Illustrative Example - Objective I aims to characterize the risk of inpatient mortality \[Primary Outcome\] and progression ...

What is the current status of trial NCT05638932?

This trial is currently completed. The enrollment target is 1,442 participants. The study started on 2020-06-16. Estimated completion is 2023-09-25.

What conditions does trial NCT05638932 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT05638932?

The interventions under investigation include: Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI) (DRUG).

Who is sponsoring clinical trial NCT05638932?

This trial is sponsored by Aetion, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05638932 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05638932's enrollment target sits among peer trials

1,442 56th of 298 higher than 243 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04754022 · 1,440 participants · NA

    Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery

  • NCT04989790 · 1,440 participants · NA

    Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children

  • NCT06122246 · 1,440 participants · NA

    PRESSURE CHECK: Find Your Path to Better Health

  • NCT06324318 · 1,440 participants · Phase 2

    Parenting in 2 Worlds Multisite Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05638932, the US trial registry maintained by the National Library of Medicine. NCT05638932 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.